Gyre Therapeutics (NASDAQ:GYRE) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Gyre Therapeutics (NASDAQ:GYRE) from a sell rating to a hold rating in a research report released on Saturday morning,Wall Street Zen reports.

A number of other research analysts also recently commented on GYRE. Weiss Ratings reissued a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Wednesday. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 6th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Gyre Therapeutics presently has an average rating of “Reduce”.

Gyre Therapeutics Trading Up 18.7%

NASDAQ GYRE opened at $4.76 on Friday. The company has a market cap of $530.79 million, a PE ratio of -23.80 and a beta of 2.14. Gyre Therapeutics has a 12 month low of $3.97 and a 12 month high of $9.14. The stock has a 50 day moving average of $6.51 and a 200-day moving average of $6.90.

Gyre Therapeutics (NASDAQ:GYRE) last issued its earnings results on Thursday, November 5th. The company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.19. Gyre Therapeutics had a negative net margin of 14.80% and a negative return on equity of 7.44%. The business had revenue of $32.93 million for the quarter, compared to the consensus estimate of $28.40 million. As a group, sell-side analysts predict that Gyre Therapeutics will post -0.61 EPS for the current fiscal year.

Institutional Trading of Gyre Therapeutics

A number of hedge funds have recently made changes to their positions in the company. SBI Securities Co. Ltd. increased its holdings in shares of Gyre Therapeutics by 1.8% during the third quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company’s stock valued at $1,244,000 after acquiring an additional 2,967 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Gyre Therapeutics in the 2nd quarter worth $83,000. BlackRock Inc. acquired a new stake in Gyre Therapeutics in the 2nd quarter valued at $6,550,000. Deutsche Bank AG bought a new stake in Gyre Therapeutics during the 2nd quarter valued at $118,000. Finally, Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics during the 2nd quarter valued at $414,000. 23.99% of the stock is owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.